Skip to content
lifestyle.marketresearchjournals.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
HCW Biologics Inc.
HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter
June 30, 2026
HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026
June 26, 2026
HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata
June 16, 2026
HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen
May 27, 2026
HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules
May 26, 2026
HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies
May 24, 2026
HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results
May 23, 2026
←
Previous Page
1
2